Effects of Silymarin and Pentoxifylline on Matrix Metalloproteinase-1 and-2 Expression and Apoptosis in Experimental Hepatic Fibrosis

被引:12
|
作者
Kara, Eray [1 ]
Coskun, Teoman [1 ]
Kaya, Yavuz [1 ]
Yumus, Okan [1 ]
Vatansever, Seda [1 ]
Var, Ahmet [1 ]
机构
[1] Celal Bayar Univ, Sch Med, Manisa, Turkey
关键词
matrix metalloproteinases; MMP-1; MMP-2; tissue inhibitor of matrix metalloproteinases; TIMP-1; TIMP-2; experimental liver fibrosis; apoptosis;
D O I
10.1016/j.curtheres.2008.12.003
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
BACKGROUND: Many therapeutic strategies ha,e been proposed to treat liver fibrosis, but no drugs have been proved effective. Matrix metalloproteinases (MMPs) have been reported to play a role in some cellular cascades of hepatic inflammation and fibrosis. OBJECTIVE: The purpose of this study was to investigate whether silymarin and pentoxifylline (PTX) have hepatoprotective and antifibrotic effects in experimental hepatic fibrosis. METHODS: Sprague-Dawley rats were divided into 4 groups: silymarin group (silymarin 4 mg/kg . d(-1) orally, common bile duct ligation [CBDL]); PTX group (PTX 2 mg/kg . d(-1) intraperitoneally, CBDL); sham group (common bile duct [CBD] exploration only); and control group (saline 1 mL/d orally, CBDL). The CBD was explored and dissected Sufficiently to allow passage of a 3/0 silk suture via midline laparotomy. Oil day 10, all animals were euthanized via cervical dislocation. Then, 5-cm(3) liver samples from the right lobe were removed for histomorphologic evaluation and 3-mL blood samples were taken via cardiac puncture for biochemical analyses. Apoptosis was determined using the terminal deoxynucleotidyltransferase-biotin nick end-Libel (TUNEL) staining method. Plasma levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyltransferase; total and indirect bilirubin concentration; hepatic MMP-1 and -2 and tissue inhibitor of MMP (TIMP)-1 and -2 activity; and transforming-growth factor (TGF)-beta(1) concentration were Measured. Collagen content was determined by measuring hydroxyproline in liver samples. Malondialdehyde (MDA) was used to estimate lipid peroxidation. RESULTS: Thirty-two adult male Sprague-Dawley rats were divided into 4 groups: silymarin group (n = 7), PTX group (1) 7), sham group (n = 9), and control group (n 9). Compared with the control group (14.6 [2.44]), mean (SD) hepatocyte apoptosis (as measured by the ratio of TUNEL-positive cells) was significantly Suppressed in the silymarin group (1.2 [0.13]; P = 0.001) and the PTX group (3.8 [0.34]; P 0.001). Mean (SD) MMP-2 activity in the silymarin group (57.35 [9.89] mu g/mL; P = 0.04) and the PTX group (46.88 [9.56] mu g/mL; P 0.04) was significantly lower than that observed in the control group (232.32 [79.76] mu g/mL). Compared with the control group (1.37 [0.38] mu g/mL), TIMP-2 activity was significantly lower in the silymarin group (0-55 [0-13] mu g/mL; P = 0.04) and the PTX group (0.42 [0.09] mu g/mL; P = 0.01). Compared with the control group (909.17 [117.35] mu g/mL), TGF-beta(1) was significantly lower in the silymarin group (518.24 [30-34] mu g/mL; P = 0.01) and the PT X group (519.57 [47.27] mu g/mL; P = 0.01). Histomorphologic changes were significantly greater in the sham group than in the silymarin and PTX groups: hemorrhage (2.44 [0.29] vs 1.29 [0.18] and 1.57 [0.20], respectively; both, P = 0.04.); sinusoidal dilatation (2.22 [0.22] vs 1.57 [0.20] and 1.71 [0.18]; both, P = 0.04); presinusoidal polymorphonuclear cell infiltration (3.44 [0.24] vs 2.57 [0.20] and 2.14 [0.26]; P = 0.03 and P = 0.008, respectively); and inflammation (3.44 [0.24] vs 2.57 [0.20] and 2.14] [0.26]; P = 0.03 and P 0.008, respectively). In the control group, all biochemical markets were elevated, Supporting the presence of liver injury. Compared with the control group (630.00 [46.80] U/L), plasma AST activity was significantly lower in the silymarin group (443.11 [78.73]; P = 0.04) and the PTX group (349.42 [34.00]; P = 0.03). Compared with the control, group (191.12 [32.93] U/L), plasma ALT activity was significantly lower in the silymarin group (86.14 [4.97]; P = 0.04) and the PTX group (84.14 [11.21]; P = 0.04). MDA concentration was significantly lower in the silymarin group compared with the control group (0.08 [0.01] VS 0.22 [0.03] nmol/mL; P = 0.004); MDA was also significantly lower in the silymarin group than in the PTX group (0.11 [0.02]; P = 0.03). CONCLUSIONS: Silymarin and PTX were associated with lower histopathologic liver damage, hepatocyte apoptosis, and regulation of extracellular matrix proteins. Lipid peroxidation in heparocytes was significantly lower in the silymarin group Compared with the PTX group. Silymarin and PTX appeared to have hepatoprotective effects in this experimental liver fibrosis model, but further clinical and experimental studies are needed. (Curr Ther Res Clin Exp. 2008;69:488-502) (C) 2008 Excerpta Medica Inc.
引用
收藏
页码:488 / 502
页数:15
相关论文
共 50 条
  • [1] Increased expression of extracellular matrix metalloproteinase inducer is associated with matrix metalloproteinase-1 and-2 in gingival tissues from patients with periodontitis
    Dong, W.
    Xiang, J.
    Li, C.
    Cao, Z.
    Huang, Z.
    JOURNAL OF PERIODONTAL RESEARCH, 2009, 44 (01) : 125 - 132
  • [2] Matrix metalloproteinase-1,-3,-13 and aggrecanase-1 and-2 are differentially expressed in experimental osteoarthritis
    Bluteau, G
    Conrozier, T
    Mathieu, P
    Vignon, E
    Herbage, D
    Mallein-Gerin, F
    BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2001, 1526 (02): : 147 - 158
  • [3] Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and-2 in type 2 diabetes
    Tayebjee, MH
    Lim, HS
    MacFadyen, R
    Lip, GYH
    DIABETES CARE, 2004, 27 (08) : 2049 - 2051
  • [4] Localization and potential role of matrix metalloproteinase-1 and tissue inhibitors of metalloproteinase-1 and-2 in different phases of bronchopulmonary dysplasia
    Dik, WA
    De Krijger, RR
    Bonekamp, L
    Naber, BAE
    Zimmermann, LJI
    Versnel, MA
    PEDIATRIC RESEARCH, 2001, 50 (06) : 761 - 766
  • [5] Tissue inhibitors of metalloproteinase-1 and-2 inhibit apoptosis of human and rat hepatic stellate cells in vitro.
    Murphy, FR
    Issa, R
    Hussain, H
    Ratnarajah, S
    Benyon, C
    Iredale, JP
    HEPATOLOGY, 2001, 34 (04) : 401A - 401A
  • [6] TGF-α Attenuates Hepatic Fibrosis: Possible Involvement of Matrix Metalloproteinase-1
    Ohyama, Tatsuya
    Sato, Ken
    Yamazaki, Yuichi
    Horiguchi, Norio
    Ichikawa, Takeshi
    Kakizaki, Satoru
    Takagi, Hitoshi
    Mori, Masatomo
    GASTROENTEROLOGY, 2011, 140 (05) : S979 - S979
  • [7] Matrix metalloproteinase-1 treatment of muscle fibrosis
    Kaar, Joel L.
    Li, Yong
    Blair, Harry C.
    Asche, Gemma
    Koepsel, Richard R.
    Huard, Johnny
    Russell, Alan J.
    ACTA BIOMATERIALIA, 2008, 4 (05) : 1411 - 1420
  • [8] Matrix metalloproteinase-1 treatment of muscle fibrosis
    Kaar, J. L.
    Li, Y.
    Blair, H. C.
    Asche, G.
    Koepsel, R. R.
    Huard, J.
    Russell, A. J.
    TISSUE ENGINEERING PART A, 2008, 14 (05) : 876 - 877
  • [9] Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition - Implications for reversibility of liver fibrosis
    Murphy, FR
    Issa, R
    Zhou, XY
    Ratnarajah, S
    Nagase, H
    Arthur, MJP
    Benyon, C
    Iredale, JP
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (13) : 11069 - 11076
  • [10] Expression of matrix metalloproteinase-2 and-9 and tissue inhibitor of metalloproteinase-1 and-2 in intraductal and nonintraductal growth type of cholangiocarcinoma
    Chae, KJ
    Rha, SY
    Oh, BK
    Koo, JS
    Kim, YJ
    Choi, J
    Park, C
    Park, YN
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (01): : 68 - 75